| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/27/2002 | WO2000056345A9 Methods for limiting scar and adhesion formation |
| 06/27/2002 | US20020082780 Natural, anti-bacterial, anti-virus, anti-herpes cream |
| 06/27/2002 | US20020082448 Administering aminoguanidine carboxylate compounds for reducing blood glucose concentration in a patient |
| 06/27/2002 | US20020082441 Useful as an intermediate in preparation of certain small molecules that are useful in therapy or prophylaxis of inflammatory and immune cell-mediated diseases |
| 06/27/2002 | US20020082436 For use as dietary supplement in human food and animal feeds |
| 06/27/2002 | US20020082435 For use in cancer therapy |
| 06/27/2002 | US20020082420 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| 06/27/2002 | US20020082419 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| 06/27/2002 | US20020082417 Compound for use in the treatment of vision defects and chronic obstructive pulmonary diseases |
| 06/27/2002 | US20020082415 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression |
| 06/27/2002 | US20020082392 Antibodies to cell-cycle regulatory proteins, and uses related thereto |
| 06/27/2002 | US20020082307 Useful for therapy of symptoms associated with respiratory illnesses |
| 06/27/2002 | US20020082306 Heating aqueous solution of polyoxyethylene-660-hydroxystearate, adding beta-carotene with stirring; adding ascorbyl palmitate and alpha-tocopoherol as antioxidant to solution; diluting with water |
| 06/27/2002 | US20020082305 Petrolatum-based nose ointment |
| 06/27/2002 | US20020082304 Containing combination inhibitor, combination inhibitor which acts both to interfere with the isolation of sympathomimetic amine from the composition and to interfere with conversion of sympathomimetic amine to another drug |
| 06/27/2002 | US20020082301 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 06/27/2002 | US20020082300 1-((5-(2-(5-tert-Butyl-2-methoxybenzamido)ethyl)-2-methoxyphen yl)- sulfonyl)-3-methylthiourea and propanolol for example |
| 06/27/2002 | US20020082299 Administering a given dosage of creatine |
| 06/27/2002 | US20020082298 Non-insulin dependent diabetes mellitus, syndrome X, hyperlipidaemia, hypertension, hyperinsulinaemia, hypercholesterinaemia, hypertriglycerinaemia, impaired glucose tolerance and related obesity |
| 06/27/2002 | US20020082295 Extraction from a fermentation broth, obtaining an ammonium salt of pravastatin from the solution, purifying the salt and transposing the salt to pravastatin sodium |
| 06/27/2002 | US20020082293 Hydroxy acids with kojic acid; topical treatment for hyperpigmentation, photodamage, aging, acne |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082291 New use of taxoid derivatives |
| 06/27/2002 | US20020082290 Treating eye condition with an angiogenesis inhibitor, EM-138, 2-(1,3-dicarboxylpropyl)isoindolin-1-one |
| 06/27/2002 | US20020082289 Fipronil amidated with a carboxylic acid having organic radical E which is enantiomerically enriched; preparing (S)-fipronil which has reduced emetic activity in animals (for oral flea and tick control) |
| 06/27/2002 | US20020082288 Ophthalmic formulations comprising an imidazoline |
| 06/27/2002 | US20020082287 Administering a prostaglandin receptor EP4 subtype antagonist; treating bone disorders such as osteoporosis and Paget's disease; works by inhibiting the bone resorption of the osteoclasts |
| 06/27/2002 | US20020082286 3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use |
| 06/27/2002 | US20020082285 Method for preventing or treating pain by administering an endothelin antagonist |
| 06/27/2002 | US20020082284 Use of thiazolidinediones for the treatment of hyperglycaemia |
| 06/27/2002 | US20020082283 Increasing the function of the N-methylaspartic acid (NMDA) receptor without the inherent side-effects associated with modulation of the glutamate binding site |
| 06/27/2002 | US20020082282 Mutual prodrug of amlodipine and atorvastatin |
| 06/27/2002 | US20020082281 Provided the agent is not a rho GTPase function inhibitor; treating pulmonary hypertension, ischemic stroke, impotence, heart failure, renal disease, esophageal motility syndrome |
| 06/27/2002 | US20020082278 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases |
| 06/27/2002 | US20020082276 Quinoline derivatives as anti-inflammatory agents |
| 06/27/2002 | US20020082275 Methods of use of gemifloxacin compounds against fluoroquinolone resistant streptococcus pneumoniae bacteria |
| 06/27/2002 | US20020082274 Preparation of sodium-hydrogen exchanger type-1 inhibitors |
| 06/27/2002 | US20020082273 Administering a chelator specific for copper (such as bathocuproine) and clioquinol to prevents formation of and/or induce resolubilization of amyloid beta peptide deposits and reduce reactive oxygen species |
| 06/27/2002 | US20020082272 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 06/27/2002 | US20020082269 Purine-2,6-dione based compounds as receptor binding assay probes and pharmaceuticals; high potency and affinity with water solubility |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082265 For treating or preventing emphysema, cancer and dermatological disorders |
| 06/27/2002 | US20020082261 Prophylactic or therapeutic agents for diseases haivng vascular dysfunction associated with insulin resistance |
| 06/27/2002 | US20020082260 Isoindolin-1-one-substituted propionamide glucokinase activators which increase insulin secretion in the treatment of type II diabetes |
| 06/27/2002 | US20020082258 Novel antitobesity and hypocholesterolemic compounds lower total cholesterol; increase high density lipoprotein (HDL) and decrease low denstiy lipoprotein |
| 06/27/2002 | US20020082257 Elevates ATP binding cassette transporter 1 expression thereby increasing efflux of cholesterol from cells by active transfer into high density lipoproteins |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082255 Substituted ureas |
| 06/27/2002 | US20020082252 Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms |
| 06/27/2002 | US20020082251 Desmethylolanzapine compositions and methods |
| 06/27/2002 | US20020082250 Beta lactams as antiproliferative agents |
| 06/27/2002 | US20020082249 Prodrugs of aspartyle protease inhibitors |
| 06/27/2002 | US20020082248 Hydrochloric or hydrobromic salt reacted with sodium hydroxide in aqueous solution; formed sodium chloride and/or bromide are continuously removed via permselective membrane; solution is concentrated and sodium salt isolated by drying |
| 06/27/2002 | US20020082246 Prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved; these include degenerative joint disorders such as osteoarthroses and disorders of connective tissue |
| 06/27/2002 | US20020082245 Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
| 06/27/2002 | US20020082244 Compositions and methods for inhibiting bone resorption |
| 06/27/2002 | US20020082243 Administering an effective amount of sulfonylamino-substituted N-aryl- or heteroacryl or alkyl or cycloalkylcarboxamide derivatives or salts, esters, amides or prodrug to treat tumor |
| 06/27/2002 | US20020082242 Compositions and methods of double-targeting virus infections and cancer cells |
| 06/27/2002 | US20020082241 Adenosine as antithrombotic |
| 06/27/2002 | US20020082240 Method for treating restenosis with a2a adenosine receptor agonists |
| 06/27/2002 | US20020082239 Administering a 6- mercaptopurine drug to a patient having immune-mediated gastrointestinal disorder and determining a level of 6-thioguanine in the patient |
| 06/27/2002 | US20020082237 Complexing a cationic polymer and/or cationic lipid with a polynucleotide in the presence of detergent, removing the detergent whereby a stable polynucleotide dellivery vehicle is produced |
| 06/27/2002 | US20020082236 A double stranded nucleic acid molecules with a first strand comprises an RNA sequence which codes for a protein of interest linked downstream of a flanking sequence and a translation initiation site inserted upstream of the RNA |
| 06/27/2002 | US20020082235 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 06/27/2002 | US20020082234 Novel prokaryotic polynucleotides, polypeptides and their uses |
| 06/27/2002 | US20020082230 Introducing an antisense oligomer into a cell, allowing the oligomer to hybridize to the mRNA of IL-15, thereby inhibiting the production of IL-15 |
| 06/27/2002 | US20020082226 Antisense antibacterial method and composition |
| 06/27/2002 | US20020082224 Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| 06/27/2002 | US20020082223 Administering to a patient a therapeutically effective amount of a steroidal glycoside or mixture to treat cancer |
| 06/27/2002 | US20020082222 Treatments for neurogenetic disorders, impulse control disorder, and wound healing |
| 06/27/2002 | US20020082221 Nitric-oxide releasing lipid molecules selected from phosphoglycerides, lipids having a sphingosine base as a backbone, a monoglyceride, a diglyceride, a glycosylacylglycerol and a sterol containing S-N=O, N-N=O or |
| 06/27/2002 | US20020082218 Certain thiol inhibitors of endothelin-converting enzyme |
| 06/27/2002 | US20020082205 Human FGF-23 gene and gene expression products |
| 06/27/2002 | US20020082201 And pharmaceutically acceptable surfactant including sodium lauryl sulfate, buffering agent to provide pH of 3.0-7.0, 0.5-10.0 weight percent colloidal silicon dioxide |
| 06/27/2002 | US20020082200 Use of inhibitors of human S-CD23 |
| 06/27/2002 | US20020082193 Inhibition of mitochondrial calcium/sodium antiporter |
| 06/27/2002 | US20020082191 Amino acid sequences of the transport proteins encoded by genes within the human genome; isolated peptide and nucleic acid molecules, methods of identifying orthologs, paralogs and modulators of the kinase peptides; brain disorders |
| 06/27/2002 | US20020082190 Amino acid sequences of the transport proteins encoded by genes within the human genome; isolated peptide and nucleic acid molecules, methods of identifying orthologs, paralogs and modulators of the kinase peptides; brain disorders |
| 06/27/2002 | US20020082189 Amino acid sequences of the kinase peptides encoded by genes within the human genome; isolated peptide and nucleic acid molecules, methods of identifying orthologs, paralogs and modulators of the kinase peptides; anticarcinogenic agents |
| 06/27/2002 | US20020081736 Transferring nucleotide sequences into cells; generate mixture of dextrin, sucrose and nucleotide sequences, incubate with cell, recover transformed cells |
| 06/27/2002 | US20020081686 Novel antimicrobial therapies |
| 06/27/2002 | US20020081682 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of bacterial infections |
| 06/27/2002 | US20020081671 Reductive amination of alpha-ketodicarboxylic acid derivatives |
| 06/27/2002 | US20020081665 Composition for use as immunomodulatory and anticarcinogenic agents |
| 06/27/2002 | US20020081659 Nucleic acids, proteins and antibodies |
| 06/27/2002 | US20020081650 Expression vectors coding protein for use in the treatment of cancer, and neovascularization defects |
| 06/27/2002 | US20020081645 Coding or classification of prion sample; obtain sample, monitor physical properties of sample, compare to control |
| 06/27/2002 | US20020081613 Detecting cancer in a tissue sample; obtain tissue sample, screen for preferential marker, presence of marker indicates cancer |
| 06/27/2002 | US20020081601 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 06/27/2002 | US20020081578 Nucleotide sequences coding preferential polypeptide for as anticarcinogenic agents |
| 06/27/2002 | US20020081360 Salts of L-amino acid having improved taste and their preparation |
| 06/27/2002 | US20020081343 Controlled ethanolic extraction, drying, and processing by supercritical fluid extractions |
| 06/27/2002 | US20020081340 Side-effect reduction of anti-cancer therapy |
| 06/27/2002 | US20020081339 Biodegradable microspheres releasing an anticancer agent are injected into the tumor, into the peritumoral area or both at the same time |
| 06/27/2002 | US20020081338 Composition for treating dry eye |
| 06/27/2002 | US20020081333 Orally administrable opioid formulations having extended duration of effect |
| 06/27/2002 | US20020081327 Topical solution of a pyrazole compound of given formula; controlling ticks: elimination of Boophilus microplus in less than 2 days, for cattle, sheep |
| 06/27/2002 | US20020081317 Bacteria rendered non-pathogenic having altered DNA adenine methylase activity, genetically engineered to express a heterologous antigen such as immunogenic antigen of a virus, protozoa, parasite or fungi |
| 06/27/2002 | US20020081315 Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 06/27/2002 | US20020081314 Starch and protein from a mixture of embryo bud and seed coat of rice and fruit body of ganoderma lucidum are decomposed by aspergills oryzae with added B vitamins, and the enzyme retain their catalytic activity; prevent autoimmune diabetes |